BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23720067)

  • 1. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
    Zhuang H; Wang J; Zhao L; Yuan Z; Wang P
    Int J Cancer; 2013 Nov; 133(10):2277-83. PubMed ID: 23720067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
    Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
    de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
    J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
    Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
    Luo S; Chen L; Chen X; Xie X
    Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
    Shiroma T; Yamaguchi M; Nagai A
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1729-31. PubMed ID: 19838036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Zheng MH; Sun HT; Xu JG; Yang G; Huo LM; Zhang P; Tian JH; Yang KH
    Biomed Res Int; 2016; 2016():5807346. PubMed ID: 27006948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
    Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
    Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
    Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].
    Seidel C; Kortmann RD
    Strahlenther Onkol; 2015 Feb; 191(2):205-7. PubMed ID: 25793246
    [No Abstract]   [Full Text] [Related]  

  • 16. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
    Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from carcinomatous meningitis by erlotinib.
    Ohara G; Kagohashi K; Kurishima K; Kawaguchi M; Nakayama H; Satoh H
    Onkologie; 2011; 34(7):394-5. PubMed ID: 21734429
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.